Dendreon’s Therapeutic Vaccine Provenge Gets “Complete Response” From FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is requesting additional clinical data to support the efficacy of Dendreon’s BLA.
You may also be interested in...
PDUFA Cliffhanger: Will FDA End The Provenge Regulatory Saga?
FDA approval of Provenge for prostate cancer could come May 1, opening the door for the launch of the first cancer immunotherapy.
PDUFA Cliffhanger: Will FDA End The Provenge Regulatory Saga?
FDA approval of Provenge for prostate cancer could come May 1, opening the door for the launch of the first cancer immunotherapy.
Chart: Oncology: The Race Is On In HRPC; Sponsors Of Niche Oncologics Struggle
Sanofi-Aventis expects to complete a rolling NDA submission for its "home grown" novel taxoid Jevtana (cabazitaxel) by the end of the first quarter, Sanofi-Aventis Global Operations President Hanspeter Spek told a Feb. 10 earning call.